Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03999229 · ClinicalTrials.gov registry record · Phase 1
S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion
A Phase 1 study of Transfusion Related Complication, sponsored by James Reynolds.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT03999229 is a Phase 1 study of Transfusion Related Complication that is actively recruiting participants, run by James Reynolds. The registered enrollment target is 35 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03999229, a Phase 1 study of Transfusion Related Complication, is actively recruiting participants, sponsored by James Reynolds.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The Purpose of the study is to test the hypothesis that administration of an S-nitrosylating (SNO) agent can improve tissue oxygenation during transfusion of packed red blood cells (RBCs).
Conditions Studied
Interventions
- DRUG Normal Saline
- DRUG SNO
- DRUG Red Blood Cell
Study Locations (1)
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2019-07-25 |
| Est. Completion | 2028-02-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03999229
The ClinicalTrials.gov registry entry for NCT03999229 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is James Reynolds, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transfusion Related Complication appearing as the primary indexed condition, and to 3 interventions - of which Normal Saline is the first listed.
NCT03999229 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT03999229 about?
NCT03999229 is a clinical study titled "S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion". The Purpose of the study is to test the hypothesis that administration of an S-nitrosylating (SNO) agent can improve tissue oxygenation during transfusion of packed red blood cells (RBCs).
What is the current status of trial NCT03999229?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2019-07-25. Estimated completion is 2028-02-29.
What conditions does trial NCT03999229 study?
This clinical trial studies the following conditions: Transfusion Related Complication.
What interventions are being tested in trial NCT03999229?
The interventions under investigation include: Normal Saline (DRUG), SNO (DRUG), Red Blood Cell (DRUG).
Who is sponsoring clinical trial NCT03999229?
This trial is sponsored by James Reynolds, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03999229 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.